Special Investigation Of J Zoloft For Panic Disorder Patients

Official Title: “Special Investigation Of J Zoloft For Panic Disorder Patients”

The objective of this surveillance is to collect information for panic disorder patients about 1) adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.

All patients with panic disorder to whom an investigator prescribes the first sertraline hydrochloride should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Intervention(s) in this Clinical Trial

• Drug: Sertraline hydrochloride
  • J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan. Dosage, Frequency: According to Japanese LPD, "The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms". Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration.

Arms, Groups and Cohorts in this Clinical Trial

• : Sertraline hydrochloride.
  • The patients of Panic disorder taking Sertraline hydrochloride.

Primary Measures

• Factors considered to affect the safety and/or efficacy of this drug.
  • Time Frame: 16 weeks
    Safety Issue?: Yes
• The incidence of adverse drug reactions.
  • Time Frame: 16 weeks
    Safety Issue?: Yes
• The number of adverse drug reactions not expected from the LPD (unknown adverse drug reactions).
  • Time Frame: 16 weeks
    Safety Issue?: Yes

Secondary Measures

• This study is a non-interventional/observational study and does not have any secondary outcomes measures.
  • Time Frame: There are no secondary outcomes for this study
    Safety Issue?: No

Inclusion Criteria:

• Patients with panic disorder need to be taking sertraline hydrochloride in order to be enrolled in the surveillance.

Exclusion Criteria:

• Patients not taking sertraline hydrochloride.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Pfizer Industry

Overall Clinical Trial Officials and Contacts

Pfizer CT.gov Call Center Study Director Pfizer  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00605917

Study ID Number: A0501092

ClinicalTrials.gov Identifier: NCT00605917

Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

To obtain contact information for a study center near you, click here.